Stocktoria
EyePoint, Inc. EYPT
Nasdaq · XNAS · stock · Laboratory Analytical Instruments · website · IPO 2005-01-27
EyePoint, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $31.4M | $43.3M | $46.0M | $41.4M | $36.9M |
| R&D expense | $221.0M | $132.9M | $64.7M | $49.6M | $28.5M |
| Operating income | -$243.4M | -$145.9M | -$75.1M | -$99.6M | -$55.3M |
| Interest expense | — | — | $1.2M | $3.2M | $5.5M |
| Income tax | $279,000 | $90,000 | $83,000 | $0 | $0 |
| Net income | -$232.0M | -$130.9M | -$70.8M | -$102.3M | -$58.4M |
| EPS (diluted) | $-3.17 | $-2.32 | $-1.82 | $-2.74 | $-2.03 |
| Operating cash flow | -$240.1M | -$126.2M | $1.9M | -$65.0M | -$50.1M |
| Free cash flow | -$243.4M | -$130.3M | -$1.6M | -$67.2M | -$50.3M |
| Cash & equivalents | $101.8M | $99.7M | $281.3M | $95.6M | $178.6M |
| Inventory | $1.8M | $2.3M | $3.9M | $2.9M | $3.6M |
| Total assets | $364.0M | $418.5M | $355.2M | $180.4M | $263.4M |
| Total liabilities | $57.9M | $82.0M | $88.9M | $84.0M | $79.0M |
| Shareholders' equity | $306.1M | $336.5M | $266.3M | $96.4M | $184.4M |
Source: SEC EDGAR filings · CIK 0001314102 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.